NYSEAMERICAN:SER Serina Therapeutics 5/14/2026 Earnings Report $1.88 +0.08 (+4.44%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings History Serina Therapeutics EPS ResultsActual EPS-$0.58Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASerina Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASerina Therapeutics Announcement DetailsQuarterDate5/14/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Serina Therapeutics Earnings HeadlinesSerina Therapeutics (NYSEAMERICAN:SER) Director Purchases $20,101.95 in StockMay 25 at 5:19 AM | americanbankingnews.comSerina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 14, 2026 | globenewswire.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.May 28 at 1:00 AM | Brownstone Research (Ad)Serina Therapeutics to Present at the 5th LNP Formulation & Process Development SummitApril 7, 2026 | globenewswire.comSerina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance PlanApril 2, 2026 | globenewswire.comSerina Therapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsMarch 25, 2026 | markets.businessinsider.comSee More Serina Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Serina Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Serina Therapeutics and other key companies, straight to your email. Email Address About Serina TherapeuticsSerina Therapeutics (NYSEAMERICAN:SER), a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.View Serina Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Microsoft Is Spending Billions on AI, But Investors Aren’t Buying ItSemtech’s Explosive Rally May Only Be Getting StartedBath & Body Works Stock Surged Despite Falling Sales—Here’s WhyAbercrombie Rallies as Strong Q1 Earnings Extend Winning StreakDick’s Sporting Goods Isn’t Done Winning YetZscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityRecord Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
